Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile.
Dahm
Felix
F
Weber
Markus
M
Clavien
Pierre-Alain
PA
D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000517:prevention & control; D016572:Cyclosporine / Q000009:adverse effects*; D006084:Graft Rejection; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D011788:Quality of Life; D012307:Risk Factors; D016559:Tacrolimus / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus